Inhibrx Biosciences, Inc.
INBX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for INBX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · INBX
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutics for oncology, with lead candidates inbrx-106 and ozekibart.
Key risk: No revenue and recurring losses
BioSniper Score
Based on 5 of 6 signals
Market Cap
$1.82B
Cash Runway
13.6 moLead Asset
inbrx-106 (Phase 2/Phase 3)Next Catalyst
Phase2_Topline · Dec 31, 2026Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 4 clinical trials · 3 catalysts for Inhibrx Biosciences, Inc..
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutics for oncology, with lead candidates inbrx-106 and ozekibart.
- Cash and equivalents of $133.3M as of 2026-06-30 [sec].
- Net loss of $36.6M for the quarter ended 2026-06-30 [sec].
- Shareholders' equity of $8.0M and total debt of $176.3M as of 2026-06-30 [sec].
- Accumulated deficit of $279.6M as of 2026-03-31 [sec_mda].
- Lead candidate inbrx-106 is in a Phase 2/3 study combined with pembrolizumab versus pembrolizumab as first-line therapy [sec_mda].
What works
- Cash runway expected to fund operations for at least 12 months from filing of the 2025 Annual Report (as of 2026-03-19) [sec_mda].
- Access to additional capital through a Term Loan facility with up to $225.0M available at lenders' discretion [sec_mda].
- Multiple clinical-stage candidates targeting oncology with differentiated mechanisms [sec_mda].
What to weigh
- No revenue generated; company has incurred net losses since inception, with a net loss of $36.6M in Q2 2026 [sec].
- Significant accumulated deficit of $279.6M as of 2026-03-31 [sec_mda].
- High debt burden of $176.3M relative to shareholders' equity of $8.0M as of 2026-06-30 [sec].
- Clinical development is inherently risky; delays or failures in trials could materially impact the company [sec].
From the filings
Quoted directly from source documents.
Accumulated deficit of $279.6M as of 2026-03-31
“accumulated deficit of $279.6 million”
SEC MD&A · March 31, 2026
Additional $225.0M available under Term Loan at lenders' discretion
“to draw down an additional $225.0 million”
SEC filings · July 16, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline · inbrx-106 — Phase 2 Readout: inbrx-106 — Topline data from the Phase 2 portion of the inbrx-106 study will provide initial efficacy and safety signals.
- 2027-04-14 · PDUFA · ozekibart — PDUFA Date: ozekibart — FDA decision on the marketing application for ozekibart; approval would mark first commercial product.
- 2029-05-01 · Phase3_Topline · inbrx-106 — Phase 3 Topline: A Phase 2/3, Randomized Study of INBRX-106 Combined With Pembrolizumab Versus Pembrolizumab as First — Topline data from the Phase 3 portion of the inbrx-106 study will inform the registrational path.
Risks & what to watch (4)›
Key risks
- No revenue and recurring losses — Company has no approved products and has incurred net losses since inception; net loss of $36.6M in Q2 2026 [sec].
- High debt and negative equity — Total debt of $176.3M exceeds shareholders' equity of $8.0M as of 2026-06-30 [sec].
- Clinical trial risks — Initiation, timing, progress, and results of clinical trials are uncertain; delays or failures could harm the company [sec].
- Dependence on additional financing — Future capital needs may require additional funding; Term Loan drawdowns are at lenders' discretion [sec_mda].
What to watch
- Phase 2 topline data for inbrx-106 expected by end of 2026 [catalyst].
- PDUFA date for ozekibart on 2027-04-14 [catalyst].
- Phase 3 topline data for inbrx-106 expected around 2029-05-01 [catalyst].
- Cash burn rate and any additional drawdowns under the Term Loan facility [sec_mda].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Inhibrx Biosciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Inhibrx Biosciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
13.6 months
OCF -$30M · Net income -$37M
Lead: Phase 2/Phase 3
2 candidates
3 upcoming, next in ~123d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
134
Total value held
$845.0M
| Holder | Shares | Value |
|---|---|---|
| perceptive advisors llc | 2,885,414 | $194.0M |
| viking global investors lp | 1,437,705 | $96.7M |
| morgan stanley | 1,263,078 | $84.9M |
| vanguard capital management llc | 972,844 | $65.4M |
| blackrock, inc. | 798,898 | $53.7M |
| woodline partners lp | 768,866 | $51.7M |
| state street corp | 550,845 | $37.0M |
| millennium management llc | 327,860 | $22.0M |
| pfm health sciences, lp | 305,431 | $20.5M |
| schonfeld strategic advisors llc | 254,827 | $17.1M |
Showing top 10 of 134 institutional holders of Inhibrx Biosciences, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 19.9%
- Days to cover
- 10.2
- Shares short
- 2,119,421
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
INBX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Inhibrx Biosciences, Inc.?
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutics for oncology, with lead candidates inbrx-106 and ozekibart.
What is Inhibrx Biosciences, Inc.'s lead drug candidate?
Inhibrx Biosciences, Inc.'s most advanced tracked candidate is inbrx-106 (Phase 2/Phase 3) for Head and Neck Squamous Cell Carcinoma (HNSCC).
What is Inhibrx Biosciences, Inc.'s next catalyst?
Inhibrx Biosciences, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: inbrx-106" — expected December 31, 2026.
Who is the CEO of Inhibrx Biosciences, Inc.?
Mr. Mark Paul Lappe is the chief executive officer of Inhibrx Biosciences, Inc. (INBX).
Where is Inhibrx Biosciences, Inc. headquartered?
Inhibrx Biosciences, Inc. (INBX) is headquartered in La Jolla, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.